Fed. Circ. Won't Rethink Alimta Double Patenting Decision
The Federal Circuit said Monday it wouldn't revisit its ruling that a patent for Eli Lilly & Co.'s chemotherapy drug Alimta is enforceable, denying generic-drug makers another chance to prove the...To view the full article, register now.
Already a subscriber? Click here to view full article